WO2008076427A3 - Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof - Google Patents

Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof Download PDF

Info

Publication number
WO2008076427A3
WO2008076427A3 PCT/US2007/025819 US2007025819W WO2008076427A3 WO 2008076427 A3 WO2008076427 A3 WO 2008076427A3 US 2007025819 W US2007025819 W US 2007025819W WO 2008076427 A3 WO2008076427 A3 WO 2008076427A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
inhibitory activity
prolyl hydroxylase
compounds exhibiting
hydroxylase inhibitory
Prior art date
Application number
PCT/US2007/025819
Other languages
French (fr)
Other versions
WO2008076427A2 (en
Inventor
Jennifer R Allen
Kaustav Biswas
Marian C Bryan
Roland Burli
Guo-Qiang Cao
Michael J Frohn
Jennifer E Golden
Stephanie Mercede
Susana Neira
Tanya Peterkin
Alexander J Pickrell
Anthony Reed
Christopher M Tegley
Xiang Wang
Original Assignee
Amgen Inc
Jennifer R Allen
Kaustav Biswas
Marian C Bryan
Roland Burli
Guo-Qiang Cao
Michael J Frohn
Jennifer E Golden
Stephanie Mercede
Susana Neira
Tanya Peterkin
Alexander J Pickrell
Anthony Reed
Christopher M Tegley
Xiang Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Jennifer R Allen, Kaustav Biswas, Marian C Bryan, Roland Burli, Guo-Qiang Cao, Michael J Frohn, Jennifer E Golden, Stephanie Mercede, Susana Neira, Tanya Peterkin, Alexander J Pickrell, Anthony Reed, Christopher M Tegley, Xiang Wang filed Critical Amgen Inc
Priority to CA2672656A priority Critical patent/CA2672656C/en
Priority to EP07867805A priority patent/EP2111399A2/en
Priority to AU2007334323A priority patent/AU2007334323B2/en
Publication of WO2008076427A2 publication Critical patent/WO2008076427A2/en
Publication of WO2008076427A3 publication Critical patent/WO2008076427A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/94—Spiro compounds containing "free" spiro atoms

Abstract

Compounds of Formula (I) and Formula (II) are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula(I) and Formula (II) have the following structures, where the definitions of the variables are provided herein.
PCT/US2007/025819 2006-12-18 2007-12-17 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof WO2008076427A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2672656A CA2672656C (en) 2006-12-18 2007-12-17 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP07867805A EP2111399A2 (en) 2006-12-18 2007-12-17 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
AU2007334323A AU2007334323B2 (en) 2006-12-18 2007-12-17 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87569306P 2006-12-18 2006-12-18
US60/875,693 2006-12-18
US96315207P 2007-08-01 2007-08-01
US60/963,152 2007-08-01

Publications (2)

Publication Number Publication Date
WO2008076427A2 WO2008076427A2 (en) 2008-06-26
WO2008076427A3 true WO2008076427A3 (en) 2009-07-23

Family

ID=39327290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/025819 WO2008076427A2 (en) 2006-12-18 2007-12-17 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof

Country Status (5)

Country Link
US (2) US7635715B2 (en)
EP (1) EP2111399A2 (en)
AU (1) AU2007334323B2 (en)
CA (1) CA2672656C (en)
WO (1) WO2008076427A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11970495B2 (en) 2017-05-09 2024-04-30 Kind Pharmaceutical Indolizine derivatives and their application in medicine

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007334323B2 (en) * 2006-12-18 2011-03-10 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2142509B1 (en) * 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
WO2010022240A1 (en) 2008-08-20 2010-02-25 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
NZ592741A (en) 2008-11-14 2013-03-28 Fibrogen Inc Thiochromene derivatives as hif hydroxylase inhibitors
DK2649998T3 (en) 2009-11-06 2015-05-04 Aerpio Therapeutics Inc Prolyl hydroxylase inhibitors
CN103608346B (en) 2011-02-02 2016-06-15 菲布罗根有限公司 As the 7-naphthyridine derivatives of hypoxia inducible factor (HIF) hydroxylase inhibitors
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
US20120219776A1 (en) * 2011-02-24 2012-08-30 Nova Chemicals Inc. Multilayer Films Containing Polyolefin-Interpolymer Resin Particle Blends
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
WO2014095534A1 (en) 2012-12-19 2014-06-26 Basf Se New substituted triazoles and imidazoles and their use as fungicides
EP2746266A1 (en) 2012-12-19 2014-06-25 Basf Se New substituted triazoles and imidazoles and their use as fungicides
WO2016034108A1 (en) 2014-09-02 2016-03-10 广东东阳光药业有限公司 Quinolinone compound and use thereof
CN105541593B (en) * 2016-02-24 2017-07-28 合肥利夫生物科技有限公司 A kind of synthetic method of pharmaceutical intermediate
CA3062972C (en) * 2017-05-09 2021-09-14 Kind Pharmaceutical Indolizine derivatives and their application in medicine
CN110156805B (en) * 2019-05-22 2020-12-11 南京合巨药业有限公司 Preparation method of 2, 3-dihydro-1, 4-dioxo [2,3-b ] pyridine-7-carboxylic acid
CN110981720B (en) * 2019-12-24 2020-11-03 河南大学 Diaryl acetate compound and preparation method thereof
CN111704551B (en) * 2020-08-20 2020-11-20 天津汉一医药科技有限公司 Preparation method of cinacalcet hydrochloride

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719164A (en) * 1995-09-28 1998-02-17 Hoechst Aktiengesellschaft Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US20050107364A1 (en) * 2003-08-25 2005-05-19 Hutchinson Douglas K. Anti-infective agents
WO2007070359A2 (en) * 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5245474B2 (en) 1972-04-19 1977-11-16
JPS5417754B2 (en) 1972-12-15 1979-07-02
CA1022544A (en) 1972-12-21 1977-12-13 Yukiyasu Murakami Process of preparing a heterocyclic acyl group-substituted cephalosporin derivative
JPS587637B2 (en) 1973-12-27 1983-02-10 住友化学工業株式会社 Shinkipenicillin no Seihou
AT328085B (en) 1974-04-23 1976-03-10 Sumitomo Chemical Co METHOD FOR MANUFACTURING NEW PENICILLIN
US4215123A (en) 1979-05-07 1980-07-29 American Home Products Corporation Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
US4468394A (en) 1981-04-02 1984-08-28 Eisai Co., Ltd. Cephalosporin compounds
US4404201A (en) 1981-11-13 1983-09-13 Warner-Lambert Company Cephalosporins
US4374138A (en) 1981-11-13 1983-02-15 Warner-Lambert Company Antibacterial amide compounds, compositions, and methods of use
US4382089A (en) 1982-03-02 1983-05-03 Warner-Lambert Company Antibacterial amide compounds, compositions thereof and methods of using them
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
US5037826A (en) 1986-10-15 1991-08-06 Schering Corporation 1-substituted naphthyridine and pyridopyrazine derivatives
SU1735288A1 (en) 1990-03-05 1992-05-23 Харьковский государственный фармацевтический институт Method for synthesis of n-r-substituted amides of hydroxyquinolone-2-carboxylic- 3-acid
JP2988739B2 (en) 1990-04-16 1999-12-13 協和醗酵工業株式会社 1,8-naphthyridin-2-one derivatives
IL100917A0 (en) 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
DE4138820A1 (en) 1991-11-26 1993-05-27 Basf Ag CHINOLIN-3-CARBONATEAMIDE, THEIR PREPARATION AND USE
AU668694B2 (en) 1991-12-19 1996-05-16 Sanofi-Synthelabo Saccharin derivative proteolytic enzyme inhibitors
US5502035A (en) 1993-08-06 1996-03-26 Tap Holdings Inc. N-terminus modified analogs of LHRH
JPH07224040A (en) 1994-02-07 1995-08-22 Fujisawa Pharmaceut Co Ltd Quinoline derivative
DE19746287A1 (en) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
GB9911047D0 (en) 1999-05-12 1999-07-14 Isis Innovation Assay method and means
WO2001085732A1 (en) 2000-05-12 2001-11-15 Kyorin Pharmaceutical Co., Ltd. Pyridobenzodiazine derivatives and processes for the preparation thereof
AU2002303145A1 (en) 2001-03-23 2002-10-08 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
CN1602360A (en) 2001-12-06 2005-03-30 法布罗根股份有限公司 Methods of increasing endogenous erythropoietin (EPO)
AU2003257822A1 (en) 2002-08-13 2004-04-30 Shionogi And Co., Ltd. Heterocyclic compound having hiv integrase inhibitory activity
AU2003286594A1 (en) 2002-10-21 2004-05-13 Irm Llc Quinolones with anti-hiv activity
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
WO2004104000A1 (en) 2003-05-23 2004-12-02 Japan Tobacco Inc. Tricyclic condensed ring compound and medical use thereof
WO2004103974A1 (en) 2003-05-23 2004-12-02 Japan Tobacco Inc. Substituted 2-oxoquinoline compound and medicinal use thereof
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005011696A1 (en) 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
MXJL06000006A (en) 2003-08-22 2006-05-04 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases.
EP1682550B1 (en) 2003-11-04 2009-12-23 Merck & Co., Inc. Substituted naphthyridinone derivatives
US8691991B2 (en) 2004-02-11 2014-04-08 Shionogi & Co., Ltd. 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors
WO2005111044A1 (en) 2004-05-17 2005-11-24 Tibotec Pharmaceuticals Ltd. 4-substituted-1,5-dihydro-pyrido[3,2-b]indol-2-ones
US20100130737A1 (en) 2005-02-18 2010-05-27 Takeda Pharmaceutical Company Limited Regulating Agent of GPR34 Receptor Function
AR055319A1 (en) 2005-03-17 2007-08-15 Wyeth Corp ISOQUINOLEIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES
JP5390184B2 (en) 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド Improved treatment of anemia
WO2006138511A2 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
AU2007218051A1 (en) 2006-02-16 2007-08-30 Fibrogen, Inc. Compounds and methods for treatment of stroke
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
AR059733A1 (en) 2006-03-07 2008-04-23 Smithkline Beecham Corp COMPOSITE DERIVED FROM GLYCIN N- REPLACED WITH BICYCLE HETEROAROMATICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE TO PREPARE A MEDICINAL PRODUCT TO TREAT ANEMIA AND PROCESS FOR PREPARATION
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
PE20080209A1 (en) 2006-06-23 2008-05-15 Smithkline Beecham Corp GLYCINE DERIVATIVES AS PROLYL HYDROXYLASE INHIBITORS
US20090011051A1 (en) 2006-09-28 2009-01-08 Roth Mark B Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds
AU2007334323B2 (en) 2006-12-18 2011-03-10 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
CA2672652C (en) 2006-12-18 2012-04-17 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
CL2008000065A1 (en) 2007-01-12 2008-09-22 Smithkline Beecham Corp COMPOUNDS DERIVED FROM N-SUBSTITUTED GLYCINE, INHIBITORS OF HIF PROLIL HYDROXYLASES; YOUR PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE ANEMIA.
EP2142509B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
AU2008241577B2 (en) 2007-04-18 2011-04-07 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
AU2008248234B2 (en) 2007-05-04 2011-02-03 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
EP2155746A2 (en) 2007-05-04 2010-02-24 Amgen, Inc Diazaquinolones that inhibit prolyl hydroxylase activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719164A (en) * 1995-09-28 1998-02-17 Hoechst Aktiengesellschaft Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US20050107364A1 (en) * 2003-08-25 2005-05-19 Hutchinson Douglas K. Anti-infective agents
WO2007070359A2 (en) * 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DEREK R. BUCKLE ET AL: "Synthesis and antiallergic activity of 2-hydroxy-3-nitro-1,4-naphthoquinones", JOURNAL OF MEDICINAL CHEMISTRY, US AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 20, no. 8, 1977, pages 1059 - 1064, XP002128782, ISSN: 0022-2623 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11970495B2 (en) 2017-05-09 2024-04-30 Kind Pharmaceutical Indolizine derivatives and their application in medicine

Also Published As

Publication number Publication date
US20090093483A1 (en) 2009-04-09
CA2672656A1 (en) 2008-06-26
US7635715B2 (en) 2009-12-22
AU2007334323B2 (en) 2011-03-10
US7928139B2 (en) 2011-04-19
AU2007334323A1 (en) 2008-06-26
US20100048572A1 (en) 2010-02-25
WO2008076427A2 (en) 2008-06-26
CA2672656C (en) 2012-03-20
EP2111399A2 (en) 2009-10-28

Similar Documents

Publication Publication Date Title
WO2008076427A3 (en) Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
WO2008137084A3 (en) Diazaquinolones that inhibit prolyl hydroxylase activity
WO2008130600A3 (en) Quinolones and azaquinolones that inhibit prolyl hydroxylase
WO2006105127A3 (en) Hydroxysteroid dehydrogenase inhibitors
WO2007136592A3 (en) 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
WO2007028135A3 (en) Imidazopyridine compounds
WO2009073497A3 (en) Prolyl hydroxylase inhibitors
WO2006066109A3 (en) Hydroxysteroid dehydrogenase inhibitors
WO2007061923A3 (en) Glucokinase activators
WO2007085895A3 (en) Fap inhibitors
WO2008034736A3 (en) Oxindole derivatives as anticancer agents
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
WO2008033562A3 (en) Kinase inhibitor compounds
WO2007070359A3 (en) Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
WO2006092213A8 (en) Pyrazolylcarboxanilides
WO2006072615A3 (en) Triazolophthalazines as pde2-inhibitors
MX2009006535A (en) Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors.
WO2009156462A3 (en) Organic compounds
WO2007133865A3 (en) Hcv/hiv inhibitors an their uses
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
WO2007053844A3 (en) Compositions and methods for treating inflammatory disorders
WO2008073452A8 (en) Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
WO2008089052A3 (en) N-substituted glycine derivatives: hydroxylase inhibitors
WO2006052568A3 (en) Tgf-beta inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867805

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2672656

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007334323

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007867805

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007334323

Country of ref document: AU

Date of ref document: 20071217

Kind code of ref document: A